Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. (Q36746794)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

main subject

phase III clinical trial

0 references

0 references

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

D W Miles

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

S L de Haas

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

L Y Dirix

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

G Romieu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

A Chan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

P Tomczak

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

L Provencher

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

P R Delmar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

S J Scherer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

language of work or name

English

0 references

publication date

19 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

108

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

1052-1060

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json

Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab

24 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619079

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619079

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619079

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619079

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619079

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619079

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619079

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619079

Vascular endothelial growth factor as a target for anticancer therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619079

Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619079

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619079

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3619079

RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br

5 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23422754

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23422754

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23422754

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2013.69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

PubMed publication ID

23422754

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422754%20AND%20SRC:MED&resulttype=core&format=json